Research assay kit KBVH420

COVID-19SARS-COV-2serum

The SARS-CoV-2 (Covid-19) Beta Neutralizing Antibody (B.1.351, B.1.351.2,B.1.351.3) ELISA Assay Kit is used as an analytical tool for the qualitative and quantitative detection all types of neutralizing antibodies against SARS-CoV-2 RBD (K417N, E484K, N501Y) in serum or plasma. SARS-CoV-2 (Covid-19) Beta Neutralizing Antibody (B.1.351, B.1.351.2,B.1.351.3) ELISA Assay Kit is for research use only and not to be used for diagnostic procedures. Size: 96 wells Standard Range: 15.625 – 2500 ng/mL Assay Principle The method employs sandwich ELISA technique. The protein-protein interaction between HRP-RBD and hACE2 can be blocked by neutralizing antibodies against SARS-CoV-2 RBD (K417N, E484K, N501Y). Samples and controls are pipetted in a blank microtitre plate and incubated with HRP conjugated human SARSCoV-2 RBD (K417N, E484K, N501Y) protein. The antibodies to SARS-CoV-2 (K417N, E484K, N501Y) present in the samples and controls bind to the SARS-CoV-2 RBD (K417N, E484K, N501Y) protein to form a complex. This solution of bound and unbound antibodies to SARS-CoV-2 Variant B.1.351 (Beta) is then pipetted into human ACE2 coated microplate. After washing to remove the bound complex of Anti-SARS-CoV-2 Variant B.1.351, B.1.351.2, B.1.351.3 (Beta) and HRP conjugated SARS-CoV-2 RBD (K417N, E484K, N501Y), the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionally to the amount of unbound Anti-SARS-CoV-2 (Covid-19) Variant B.1.351, B.1.351.2, B.1.351.3 (Beta) present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.